AC-T for Breast Cancer: 9 Real Stories

Stage IV HR-Positive Invasive Lobular Carcinoma: Ann's Patient Story

Patient Info: Ann, Female | Stage IV

Biomarkers: ER-positive; HER2-negative

Metastatic Site: peritoneum; intestines/bowel

Ann was living with metastatic invasive lobular breast cancer involving the peritoneum and bowel. After 9 months of recurrence treatment, she underwent successful ileostomy reversal and regained greater freedom to travel.

breastcancer.orgRead more →

Stage IV Triple-Negative Breast Cancer: Erin's Patient Story

Patient Info: Erin, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; later tumor responded to androgen signaling

Metastatic Site: Lung; brain

As of June 2026, Erin was living with metastatic triple-negative breast cancer involving lung and brain, with tumors shrinking on ongoing Gemzar plus carboplatin chemotherapy every 2 weeks.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Callie's Survivor Story

Patient Info: Callie, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of June 2026, Callie described survivorship after mastectomy, ACT chemotherapy, reconstruction, and hysterectomy for Stage IIB ER-positive IDC, with all cancer-directed treatment completed by the end of 2019.

The Patient StoryRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient StoryRead more →

Stage III HR-Positive Invasive Lobular Carcinoma: Katie's Patient Story

Patient Info: Katie, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; genetic testing negative

As of February 2025, Katie was a few months beyond active treatment for Stage III ER-positive, PR-positive, HER2-negative ILC and was adjusting to maintenance therapy with Verzenio, Lupron, and Letrozole.

Lobular Breast Cancer AllianceRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee, Female, Under 40 | Stage IV

Biomarkers: ER-positive

Metastatic Site: Bones

As of October 2024, Dee was living with Stage IV metastatic ER-positive breast cancer after bone metastases were found in 2023 and had adapted to treatment with ribociclib.

The Patient StoryRead more →

Triple-negative breast cancer: partial response to TAC chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Triple-negative breast cancer with EGFR positivity and high Ki-67; BRCA1 staining was positive by IHC.

After 1 cycle of TAC chemotherapy, the large ulcerated breast tumor shrank enough for surgery. Radical mastectomy with adjacent flap transfer achieved clear margins and no nodal metastatic cancer; she was recovering at home while awaiting planned postoperative AC-T chemotherapy.

PubMed CentralRead more →

Stage III Invasive Lobular Carcinoma: Harvey's Patient Story

Patient Info: Harvey, Male, 50s | Stage III

Biomarkers: Genetic testing negative

Harvey was in active treatment for male Stage IIIC grade 3 ILC after right mastectomy and initiation of AC-T chemotherapy, with radiation and endocrine/targeted therapy planned as of March 2024.

Lobular Breast Cancer AllianceRead more →